Objective To compare the resistance of metallo-β-lactamase -producting Pseudomonas aeruginosa between burn ward and other wards, so as to provide basis for reasonable use of antimicrobial agents. Methods BD Phoenix-100 bacteria identification and drug sensitivity analyzer was used to detect Pseudomonas aeruginosa and its susceptibility, and disc synergy method was used for the screening of metallo-v-lactamase -producting Pseudomonas aeruginosa. Results Of 68 strains of Pseudomonas aeruginosa, 9 strains (13.2%) were metallo-β-lactamase (MBL) positive. Among the 9metallo-β-lactamase positive strains, 7 strains were from the burn ward and 2 strains from other wards. The resistance rate of the MBL-producing strains to ceftazidime, cefotaxime, imipenem, ciprofloxacin, amikacin, gentamicin, piperacillin and aztreonam was respectively 100.0%, 100. 0%, 88.9%, 66.7%, 88.9%, 100,0%, 100.0%, and 88.9%, obviously higher than that of non-MBL-pro-ducing Pseudomonas aeruginosa. Conclusion The rate of MBL-producing Pseudomonas aeruginosa is obviously higher in burn ward than that in other wards. The resistance of MBL-producing Pseudomonas aeruginosa is high against commonly used antimicrobial agents. Clinical use of antibiotics should he based on the antimicrobial susceptibility test results.

【Objective】To observe the effect of acupoint external application of herbal drugs on pathological changes of nasal mucosa of allergic rhinitis mice. 【Methods】 Sixty BALB/c mice were divided into 5 groups: A(normal),B(model),C(treated with external application of herbal drugs on acupoints),D(treated with dexamethasone) and E(treated with PBS).Except group A,the mice in other groups were sensitized by ovalbumin(OVA).On the 15~(th) of the first sensitization,group C received external application of medicinal disc(mainly composed of Semen Sinapis, Rhizoma Corydalis,Herba Asari,Radix Kansui,Fructus Xanthii,etc.) on Dazhui (GV14)point,group D received intraperitoneal injection of 0.1?g/L dexamethasone(0.5?mL for each mouse) one hour before nasal dripping of OVA solution,and group E received external application of paper disc on Dazhui point and intraperitoneal injection of(0.1?g/L) PBS(0.5 mL for each mouse) one hour before nasal dripping of OVA solution,qd,for 4 weeks.After treatment,the mice were executed and the nasal mucosa was fixed in 4% paraformaldehyde.Routine paraffin slices were prepared and stained by haematoxylin and eosin.The pathological features of nasal mucosa were observed under light microscope,and eosinophil(EOS),neutrophil and lymphocyte count was performed in different groups.【Results】Compared to group A,the infiltration of EOS and neutrophil in nasal mucosa was obvious in group B(P0.05).【Conclusion】The infiltration of EOS in nasal mucosa plays an important role in the pathogenesis of allergic rhinitis and the decrease of EOS infiltration may be one of the therapeutic mechanism of external application of herbal drugs on acupoints for allergic rhinitis.

Obiective To investigate the molecular characteristics of heteroresistant vancomycinintermediate Staphylococcus aureus(hVISA)in China and analyze the differences of the molecular characteristics between hVISA and VSSA(vancomycin-susceptible Staphylococcus aureus)isolates.Methods A total of 3 15 non-repetitive MBSA were collected from the national surveillance program in China in 2007.The isolates of hVISA were confirmed by modified population analysis profile-area under the curve(PAP-AUC).The genotypes of agr and SCCmec were determined by multiplex PCR,and spa typing was performed bv PCR and DNA sequencing.The pvl gene was detected bv PCR Results The prevalence of hVISA was 9.5%(30/315).Among 315 MRSA,SCCmec Ⅲ was the most popular type,which was found in 234 isolates(234/315,74.3%),followed by SCCmec Ⅱ,which was identified in 56 isolates (56/315,17.8%).The rate of SCCmec Ⅱ in hVISA(46.7%)was significantly hisher than in VSSA (14.7%,X~2=18.93,P＜0.001).The most prevalent agr type among 315 MRSA was agr 1 accounting for 73.6%(232/315).The agr 2 accounted for 18.7%(59/315),and agr 3 and agr 4 were very rare in clinical isolates.It was different in agr types between the two groups.The rate of agr 2 in hVISA(53.4%)was higher than in VSSA(15.1%).X~2 value was 26.08 and P value was less than 0.001 through X~2 test.There was a statistical significance in the result.There were 4 spa types in hVISA isolates,including t002 (13 isolates),t037(9 isolates),t030(6 isolates),and 1548(2 isolates).The pvl positive MRSA isolates were very low,accounting for 1.6%(5/315).Conclusions The prevalence of hVISA was relatively higher in China.Compared to VSSA,the majority(53.4%)of the hVISA strains were agr 2,which was obviously different from VSSA.hVISA isolates were more diverse by spa typing,

Objective To develop a new botox-like polypeptide with anti-wrinkle and anti-aging functions, which will be used in the field of cosmetics and dermatology. Methods A series of new peptide compounds were synthesized via modifying the structure of SYN-AKE by peptide synthesis technology. Simulating muscle contraction by using co-culture model of human muscle cells and mouse embryonic spinal cord neurons to test the effects. Results Six new synthetic peptides were selected. The results showed that the muscle contraction frequency was lowered by adding C19 H30 N5 O4 compound than adding SYN-AKE in 1 min(P<0.05). Conclusion C19H30N5O4 is expected to become a new cosmetic peptide raw material and dermatology drug in the field of anti-wrinkle and anti-aging.

OBJECTIVETo report on a case of therapy-related acute monocytic leukemia(t-AML) with t(11;17) (q23;q21)/MLL-AF17q after successful treatment for acute promyelocytic leukemia(APL) with t(15;17) (q22;q21)/PML-RARα.

METHODSA MICM method (bone marrow morphology(M), immunophenotype(I), cytogenetics(C), and molecular biology(M)) was used for the diagnosis and classification of the disease at the time of onset and transformation.

RESULTSThe patient was initially identified with typical morphology and immunophenotype of APL. She has carried t(15;17)(q22;q21) and PML-RARα fusion gene but was without t(11;17)(q23;q21) or MLL gene abnormalities. After 13 months of successful treatment, she has transformed to AML with typical morphology and immunophenotype. t(11;17)(q23;q21) and MLL-AF17q fusion gene were detected in her bone marrow sample, while no PLZF-RARα fusion gene was detected by real-time quantitative reverse-transcription PCR(RQ-PCR) and fluorescence in situ hybridization(FISH).

CONCLUSIONt-AML is a serious complication after successful treatment of APL. t(11;17)(q23;q21) is not specific for the diagnosis of variant APL and can also be detected in t-AML. RQ-PCR and FISH are essential for the diagnosis of such patients.

Chromosomes, Human, Pair 11 ; Chromosomes, Human, Pair 15 ; Chromosomes, Human, Pair 17 ; Female ; Humans ; In Situ Hybridization, Fluorescence ; Leukemia, Monocytic, Acute ; genetics ; Leukemia, Promyelocytic, Acute ; genetics ; Middle Aged ; Neoplasms, Second Primary ; genetics

BACKGROUNDSignificant efforts have been made to identify factors that differentiate patients treated with novel therapies, such as bortezomib in multiple myeloma (MM). The exact expression pattern and prognostic value of the cancer/testis antigen preferentially expressed antigen of melanoma (PRAME) in MM are unknown and were explored in this study.

METHODSThe transcript level of PRAME was detected in bone marrow specimens from 100 newly diagnosed MM patients using real-time quantitative polymerase chain reaction, and the prognostic value of PRAME was determined through retrospective survival analysis. PRAME expression higher than the upper limit of normal bone marrow was defined as PRAME overexpression or PRAME (+).

RESULTSSixty-two patients (62.0%) overexpressed PRAME. PRAME overexpression showed no prognostic significance to either overall survival (n = 100) or progression-free survival (PFS, n = 96, all P > 0.05) of patients. The patients were also categorized according to regimens with or without bortezomib. PRAME overexpression tended to be associated with a lower two-year PFS rate in patients treated with non-bortezomib-containing regimens (53.5% vs. 76.9%, P = 0.071). By contrast, it was not associated with the two-year PFS rate in patients with bortezomib-containing regimens (77.5% vs. 63.9%, P > 0.05). When the patients were categorized into PRAME (+) and PRAME (-) groups, treatment with bortezomibcontaining regimens predicted a higher two-year PFS rate in PRAME (+) patients (77.5% vs. 53.5%, P = 0.027) but showed no significant effect on two-year PFS rate in PRAME (-) patients (63.9% vs. 76.9%, P > 0.05).

CONCLUSIONPRAME overexpression might be an adverse prognostic factor of PFS in MM patients treated with non-bortezomib-containing regimens. Bortezomib improves PFS in patients overexpressing PRAME.

Adult ; Aged ; Aged, 80 and over ; Antigens, Neoplasm ; metabolism ; Boronic Acids ; therapeutic use ; Bortezomib ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma ; drug therapy ; metabolism ; mortality ; Pyrazines ; therapeutic use ; Real-Time Polymerase Chain Reaction ; Young Adult